Talampanel

Source: Wikipedia, the free encyclopedia.
Talampanel
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • (8R)-7-Acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine
JSmol)
  • Nc4ccc(cc4)C(=NN2C(=O)C)c3cc1OCOc1cc3CC2C
  • InChI=1S/C19H19N3O3/c1-11-7-14-8-17-18(25-10-24-17)9-16(14)19(21-22(11)12(2)23)13-3-5-15(20)6-4-13/h3-6,8-9,11H,7,10,20H2,1-2H3/t11-/m1/s1 ☒N
  • Key:JACAAXNEHGBPOQ-LLVKDONJSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Talampanel (

amyotrophic lateral sclerosis (ALS).[4]

As of May 2010, results from the trial for ALS have been found negative.[5] Talampanel is not currently under development.

Talampanel acts as a

non-competitive antagonist of the AMPA receptor, a type of ionotropic glutamate receptor in the central nervous system.[6]

It showed effectiveness for epilepsy in clinical trials but its development was suspended due to its poor

terminal half-life (3 hours) that necessitated multiple doses per day.[7]

References

  1. S2CID 72918370
    .
  2. S2CID 45026113
    .
  3. PMID 20143438
    .
  4. S2CID 7388452
    .
  5. ^ "Talampanel Trial". alsa.org. May 2010. Archived from the original on 2011-03-23.
  6. PMID 19220413
    .
  7. PMID 26920691
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talampanel&oldid=1213384362"